2024
DOI: 10.1002/nau.25399
|View full text |Cite
|
Sign up to set email alerts
|

Safety and efficacy of an α1‐blocker plus mirabegron compared with an α1‐blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta‐analysis

Sender Herschorn,
Tufan Tarcan,
Yuan‐Hong Jiang
et al.

Abstract: AimAntimuscarinics and the β3‐adrenoreceptor agonist, mirabegron, are commonly used for treating patients with overactive bladder (OAB) and α1‐adrenoreceptor antagonists (α1‐blockers) are the main pharmacological agents used for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). As these conditions commonly occur together, the aim of this systematic review was to identify publications that compared the use of an α1‐blocker plus mirabegron with an α1‐blocker plus antim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 46 publications
0
1
0
Order By: Relevance
“…Anticholinergics (AC), beta-3 agonists (B3) and phosphodiesterase-5 inhibitors have more recently been recommended as mono or add on therapy to treat storage phase overactive bladder (OAB) symptoms. 2 When medical treatment fails, surgical treatment aiming to decrease the bladder outflow resistance is generally recommended for patients with low flow rates and any degree of prostatic enlargement. Currently, there are different types of surgical options which can be classified as bladder outflow reduction surgery (BORRS) and the type of BORRS is decided according to patient's and physician's preferences.…”
Section: Introductionmentioning
confidence: 99%
“…Anticholinergics (AC), beta-3 agonists (B3) and phosphodiesterase-5 inhibitors have more recently been recommended as mono or add on therapy to treat storage phase overactive bladder (OAB) symptoms. 2 When medical treatment fails, surgical treatment aiming to decrease the bladder outflow resistance is generally recommended for patients with low flow rates and any degree of prostatic enlargement. Currently, there are different types of surgical options which can be classified as bladder outflow reduction surgery (BORRS) and the type of BORRS is decided according to patient's and physician's preferences.…”
Section: Introductionmentioning
confidence: 99%